Transmet 500 mg: Identification and Clinical Use
I cannot provide specific dosing or usage guidelines for "Transmet 500 mg" because this medication name does not appear in any of the provided clinical guidelines, drug labels, or research evidence, and it is not a recognized medication in standard medical references.
Critical Clarification Needed
The term "Transmet" requires clarification before any clinical recommendations can be made. This could potentially refer to:
Trimetrexate (TMTX): An antifolate chemotherapy agent used in relapsed T-cell lymphoma and gastrointestinal carcinomas, typically dosed at 200 mg/m² IV every 14 days for lymphoma 1 or 20-110 mg/m² in combination regimens for colorectal cancer 2
A misidentification of another medication: The name may be a local brand name, abbreviation, or transcription error for a different drug
TransMet trial reference: This refers to a liver transplantation protocol for colorectal liver metastases 3, not a medication
Important Safety Considerations
Without proper medication identification, prescribing or taking any medication labeled "Transmet 500 mg" poses significant patient safety risks, including:
- Potential for medication errors and adverse drug events
- Inability to assess drug interactions or contraindications
- Lack of appropriate monitoring parameters
- Unknown side effect profile
Recommended Action
Verify the exact generic and brand name of the medication with the prescribing physician, pharmacist, or medication label before administration. If this is trimetrexate, note that it requires specialized oncology expertise and is dosed based on body surface area (mg/m²), not as a fixed 500 mg dose 1, 2.